2006

ORIGINAL MANUSCRIPTS

Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
F Millot, J Guilhot, B Nelken, T Leblanc, E S De Bont, A N Békassy, H Gadner, S Sufliarska, J Stary, H Gschaidmeier, F Guilhot and M Suttorp

2005

ORIGINAL MANUSCRIPTS

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL
F X E Gruber, T Lamark, A Ånonli, M A Sovershaev, M Olsen, T Gedde-Dahl, H Hjort-Hansen and B Skogen

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib
L C Crossman, T O'Hare, T Lange, S G Willis, E P Stoffregen, A S Corbin, S G O'Brien, M C Heinrich, B J Druker, P G Middleton and M W N Deininger

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming, J Howard, C Andreasson, M Bua, E Olavarria, A Rahemtulla, F Dazzi, E Kanfer, J M Goldman and J F Apperley

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance
Y K Lee, T D Shanafelt, N D Bone, A K Strege, D F Jelinek and N E Kay

Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells
M Farahani, A T Treweeke, C H Toh, K J Till, R J Harris, J C Cawley, M Zuzel and H Chen

2004

ORIGINAL MANUSCRIPTS

KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32)
R L Levine, M Wadleigh, D W Sternberg, I Wlodarska, I Galinsky, R M Stone, D J DeAngelo, D Gary Gilliland and J Cools

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate
T Illmer, M Schaich, U Platzbecker, J Freiberg-Richter, U Oelschlägel, M von Bonin, S Pursche, T Bergemann, G Ehninger and E Schleyer

Imatinib sensitizes CLL lymphocytes to chlorambucil
R Aloyz, K Grzywacz, Z-Y Xu, M Loignon, M A Alaoui-Jamali and L Panasci

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro
K Cwynarski, R Laylor, E Macchiarulo, J Goldman, G Lombardi, J V Melo and F Dazzi

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia
C Terre, V Eclache, P Rousselot, M Imbert, C Charrin, C Gervais, M J Mozziconacci, O Maarek, H Mossafa, N Auger, N Dastugue, P Talmant, J Van den Akker, C Leonard, F N'Guyen Khac, F Mugneret, F Viguié, M Lafage-Pochitaloff, J N Bastie, G L Roux, F Nicolini, F Maloisel, N Vey, G Laurent, C Recher, M Vigier, Y Yacouben, S Giraudier, J P Vernant, B Salles, J Roussi, S Castaigne, V Leymarie, G Flandrin, M Lessard & On behalf of France Intergroupe pour la Leucemie Myeloide Chronique (FILMC)